Skip to main content
Top
Published in: Rheumatology International 10/2012

01-10-2012 | Original Article

Implication of MMP-9 and urokinase plasminogen activator (uPA) in the activation of pro-matrix metalloproteinase (MMP)-13

Authors: Kyoung Soo Kim, Yeon-Ah Lee, Hyun Mi Choi, Myung Chul Yoo, Hyung-In Yang

Published in: Rheumatology International | Issue 10/2012

Login to get access

Abstract

We examined whether the expression and activation of pro-matrix metalloproteinase (MMP)-1 varies from that of pro-MMP-13 in the joint fluid of osteoarthritis (OA) and rheumatoid arthritis (RA) patients. To do this, joint fluid was collected from 34 RA and 34 OA patients. The collagenase (pro-MMP-1 and MMP-13, total MMP-1, and MMP-13), gelatinase (total MMP-2 and MMP-9), stromelysin (total MMP-3), matrilysin (total MMP-7), uPA, and tissue inhibitor of MMP (TIMP) levels were measured by ELISA. The level of total MMP-1 in RA joint fluids was similar to that of the OA joint fluid. In contrast, the level of total MMP-13 in the RA group was significantly higher than that of the OA group. Among various MMPs (MMP-2, MMP-3, MMP-7, and MMP-9), only MMP-9 was strongly associated with total MMP-13 in both RA and OA. The level of uPA was also strongly associated with MMP-13 in RA but not OA, while the level of TIMP-1 and TIMP-2 was not significantly different between RA and OA. In conclusion, MMP-9 and uPA might be involved in the activation of pro-MMP-13 through unknown mechanisms in arthritic diseases.
Literature
1.
go back to reference Mor A, Abramson SB, Pillinger MH (2005) The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction. Clin Immunol 115(2):118–128PubMedCrossRef Mor A, Abramson SB, Pillinger MH (2005) The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction. Clin Immunol 115(2):118–128PubMedCrossRef
2.
go back to reference Weinberg JB, Wortham TS, Misukonis MA, Patton KL, Chitneni SR (1993) Synovial mononuclear phagocytes in rheumatoid arthritis and osteoarthritis: quantitative and functional aspects. Immunol Invest 22(5):365–374PubMedCrossRef Weinberg JB, Wortham TS, Misukonis MA, Patton KL, Chitneni SR (1993) Synovial mononuclear phagocytes in rheumatoid arthritis and osteoarthritis: quantitative and functional aspects. Immunol Invest 22(5):365–374PubMedCrossRef
4.
go back to reference Murphy G, Knauper V, Atkinson S, Butler G, English W, Hutton M et al (2002) Matrix metalloproteinases in arthritic disease. Arthritis Res 4(Suppl 3):S39–S49PubMedCrossRef Murphy G, Knauper V, Atkinson S, Butler G, English W, Hutton M et al (2002) Matrix metalloproteinases in arthritic disease. Arthritis Res 4(Suppl 3):S39–S49PubMedCrossRef
5.
go back to reference Burrage PS, Mix KS, Brinckerhoff CE (2006) Matrix metalloproteinases: role in arthritis. Front Biosci 11:529–543PubMedCrossRef Burrage PS, Mix KS, Brinckerhoff CE (2006) Matrix metalloproteinases: role in arthritis. Front Biosci 11:529–543PubMedCrossRef
6.
go back to reference Vincenti MP, Brinckerhoff CE (2002) Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors. Arthritis Res 4(3):157–164PubMedCrossRef Vincenti MP, Brinckerhoff CE (2002) Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors. Arthritis Res 4(3):157–164PubMedCrossRef
7.
go back to reference Knauper V, Cowell S, Smith B, Lopez-Otin C, O’Shea M, Morris H et al (1997) The role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction. J Biol Chem 272(12):7608–7616PubMedCrossRef Knauper V, Cowell S, Smith B, Lopez-Otin C, O’Shea M, Morris H et al (1997) The role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction. J Biol Chem 272(12):7608–7616PubMedCrossRef
8.
go back to reference Krane SM, Byrne MH, Lemaitre V, Henriet P, Jeffrey JJ, Witter JP et al (1996) Different collagenase gene products have different roles in degradation of type I collagen. J biol chem 271(45):28509–28515PubMedCrossRef Krane SM, Byrne MH, Lemaitre V, Henriet P, Jeffrey JJ, Witter JP et al (1996) Different collagenase gene products have different roles in degradation of type I collagen. J biol chem 271(45):28509–28515PubMedCrossRef
9.
go back to reference Knauper V, Lopez-Otin C, Smith B, Knight G, Murphy G (1996) Biochemical characterization of human collagenase-3. J Biol Chem 271(3):1544–1550PubMedCrossRef Knauper V, Lopez-Otin C, Smith B, Knight G, Murphy G (1996) Biochemical characterization of human collagenase-3. J Biol Chem 271(3):1544–1550PubMedCrossRef
10.
go back to reference Hu B, Kapila YL, Buddhikot M, Shiga M, Kapila S (2000) Coordinate induction of collagenase-1, stromelysin-1 and urokinase plasminogen activator (uPA) by the 120-kDa cell-binding fibronectin fragment in fibrocartilaginous cells: uPA contributes to activation of procollagenase-1. Matrix Biol 19(7):657–669PubMedCrossRef Hu B, Kapila YL, Buddhikot M, Shiga M, Kapila S (2000) Coordinate induction of collagenase-1, stromelysin-1 and urokinase plasminogen activator (uPA) by the 120-kDa cell-binding fibronectin fragment in fibrocartilaginous cells: uPA contributes to activation of procollagenase-1. Matrix Biol 19(7):657–669PubMedCrossRef
11.
go back to reference Nagase H, Suzuki K, Morodomi T, Enghild JJ, Salvesen G (1992) Activation mechanisms of the precursors of matrix metalloproteinases 1, 2 and 3. Matrix Suppl 1:237–244PubMed Nagase H, Suzuki K, Morodomi T, Enghild JJ, Salvesen G (1992) Activation mechanisms of the precursors of matrix metalloproteinases 1, 2 and 3. Matrix Suppl 1:237–244PubMed
12.
go back to reference Murphy G, Knauper V (1997) Relating matrix metalloproteinase structure to function: why the “hemopexin” domain? Matrix Biol 15(8–9):511–518PubMedCrossRef Murphy G, Knauper V (1997) Relating matrix metalloproteinase structure to function: why the “hemopexin” domain? Matrix Biol 15(8–9):511–518PubMedCrossRef
13.
go back to reference Muroski ME, Roycik MD, Newcomer RG, Van den Steen PE, Opdenakker G, Monroe HR et al (2008) Matrix metalloproteinase-9/gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis. Curr Pharm Biotechnol 9(1):34–46PubMedCrossRef Muroski ME, Roycik MD, Newcomer RG, Van den Steen PE, Opdenakker G, Monroe HR et al (2008) Matrix metalloproteinase-9/gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis. Curr Pharm Biotechnol 9(1):34–46PubMedCrossRef
14.
go back to reference Sato H, Kinoshita T, Takino T, Nakayama K, Seiki M (1996) Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2. FEBS Lett 393(1):101–104PubMedCrossRef Sato H, Kinoshita T, Takino T, Nakayama K, Seiki M (1996) Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2. FEBS Lett 393(1):101–104PubMedCrossRef
15.
go back to reference Sternlicht MD, Werb Z (2001) How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17:463–516PubMedCrossRef Sternlicht MD, Werb Z (2001) How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17:463–516PubMedCrossRef
16.
go back to reference Weiss SJ, Peppin G, Ortiz X, Ragsdale C, Test ST (1985) Oxidative autoactivation of latent collagenase by human neutrophils. Science 227(4688):747–749PubMedCrossRef Weiss SJ, Peppin G, Ortiz X, Ragsdale C, Test ST (1985) Oxidative autoactivation of latent collagenase by human neutrophils. Science 227(4688):747–749PubMedCrossRef
17.
go back to reference Fu X, Kassim SY, Parks WC, Heinecke JW (2003) Hypochlorous acid generated by myeloperoxidase modifies adjacent tryptophan and glycine residues in the catalytic domain of matrix metalloproteinase-7 (matrilysin): an oxidative mechanism for restraining proteolytic activity during inflammation. J Biol Chem 278(31):28403–28409PubMedCrossRef Fu X, Kassim SY, Parks WC, Heinecke JW (2003) Hypochlorous acid generated by myeloperoxidase modifies adjacent tryptophan and glycine residues in the catalytic domain of matrix metalloproteinase-7 (matrilysin): an oxidative mechanism for restraining proteolytic activity during inflammation. J Biol Chem 278(31):28403–28409PubMedCrossRef
18.
go back to reference Ahrens D, Koch AE, Pope RM, Stein-Picarella M, Niedbala MJ (1996) Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis. Arthritis Rheum 39(9):1576–1587PubMedCrossRef Ahrens D, Koch AE, Pope RM, Stein-Picarella M, Niedbala MJ (1996) Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis. Arthritis Rheum 39(9):1576–1587PubMedCrossRef
19.
go back to reference Gruber BL, Sorbi D, French DL, Marchese MJ, Nuovo GJ, Kew RR et al (1996) Markedly elevated serum MMP-9 (gelatinase B) levels in rheumatoid arthritis: a potentially useful laboratory marker. Clin Immunol Immunopathol 78(2):161–171PubMedCrossRef Gruber BL, Sorbi D, French DL, Marchese MJ, Nuovo GJ, Kew RR et al (1996) Markedly elevated serum MMP-9 (gelatinase B) levels in rheumatoid arthritis: a potentially useful laboratory marker. Clin Immunol Immunopathol 78(2):161–171PubMedCrossRef
20.
go back to reference Prince HE (2005) Biomarkers for diagnosing and monitoring autoimmune diseases. Biomarkers 10(Suppl 1):S44–S49PubMedCrossRef Prince HE (2005) Biomarkers for diagnosing and monitoring autoimmune diseases. Biomarkers 10(Suppl 1):S44–S49PubMedCrossRef
21.
go back to reference Miller MC, Manning HB, Jain A, Troeberg L, Dudhia J, Essex D et al (2009) Membrane type 1 matrix metalloproteinase is a crucial promoter of synovial invasion in human rheumatoid arthritis. Arthritis Rheum 60(3):686–697PubMedCrossRef Miller MC, Manning HB, Jain A, Troeberg L, Dudhia J, Essex D et al (2009) Membrane type 1 matrix metalloproteinase is a crucial promoter of synovial invasion in human rheumatoid arthritis. Arthritis Rheum 60(3):686–697PubMedCrossRef
22.
go back to reference Hayashi N, Nishimura K, Kumagai S (2008) New biomarkers for rheumatoid arthritis. Rinsho Byori 56(4):297–308PubMed Hayashi N, Nishimura K, Kumagai S (2008) New biomarkers for rheumatoid arthritis. Rinsho Byori 56(4):297–308PubMed
23.
go back to reference Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K et al (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2(10):737–744PubMedCrossRef Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K et al (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2(10):737–744PubMedCrossRef
24.
go back to reference Itoh T, Matsuda H, Tanioka M, Kuwabara K, Itohara S, Suzuki R (2002) The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. J Immunol 169(5):2643–2647PubMed Itoh T, Matsuda H, Tanioka M, Kuwabara K, Itohara S, Suzuki R (2002) The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. J Immunol 169(5):2643–2647PubMed
25.
go back to reference Kim KS, Choi HM, Lee YA, Choi IA, Lee SH, Hong SJ et al (2011) Expression levels and association of gelatinases MMP-2 and MMP-9 and collagenases MMP-1 and MMP-13 with VEGF in synovial fluid of patients with arthritis. Rheumatol Int 2011 31(4):543–547 Kim KS, Choi HM, Lee YA, Choi IA, Lee SH, Hong SJ et al (2011) Expression levels and association of gelatinases MMP-2 and MMP-9 and collagenases MMP-1 and MMP-13 with VEGF in synovial fluid of patients with arthritis. Rheumatol Int 2011 31(4):543–547
26.
go back to reference Santos LL, Morand EF, Hutchinson P, Boyce NW, Holdsworth SR (1997) Anti-neutrophil monoclonal antibody therapy inhibits the development of adjuvant arthritis. Clin Exp Immunol 107(2):248–253PubMedCrossRef Santos LL, Morand EF, Hutchinson P, Boyce NW, Holdsworth SR (1997) Anti-neutrophil monoclonal antibody therapy inhibits the development of adjuvant arthritis. Clin Exp Immunol 107(2):248–253PubMedCrossRef
27.
go back to reference Busso N, Peclat V, So A, Sappino AP (1997) Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints. Ann Rheum Dis 56(9):550–557PubMedCrossRef Busso N, Peclat V, So A, Sappino AP (1997) Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints. Ann Rheum Dis 56(9):550–557PubMedCrossRef
28.
go back to reference Li J, Ny A, Leonardsson G, Nandakumar KS, Holmdahl R, Ny T (2005) The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type II-induced arthritis. Am J Pathol 166(3):783–792PubMedCrossRef Li J, Ny A, Leonardsson G, Nandakumar KS, Holmdahl R, Ny T (2005) The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type II-induced arthritis. Am J Pathol 166(3):783–792PubMedCrossRef
29.
go back to reference Jin T, Tarkowski A, Carmeliet P, Bokarewa M (2003) Urokinase, a constitutive component of the inflamed synovial fluid, induces arthritis. Arthritis Res Ther 5(1):R9–R17PubMedCrossRef Jin T, Tarkowski A, Carmeliet P, Bokarewa M (2003) Urokinase, a constitutive component of the inflamed synovial fluid, induces arthritis. Arthritis Res Ther 5(1):R9–R17PubMedCrossRef
30.
go back to reference Drummond AH, Beckett P, Brown PD, Bone EA, Davidson AH, Galloway WA et al (1999) Preclinical and clinical studies of MMP inhibitors in cancer. Ann N Y Acad Sci 878:228–235PubMedCrossRef Drummond AH, Beckett P, Brown PD, Bone EA, Davidson AH, Galloway WA et al (1999) Preclinical and clinical studies of MMP inhibitors in cancer. Ann N Y Acad Sci 878:228–235PubMedCrossRef
31.
go back to reference Purcell WT, Rudek MA, Hidalgo M (2002) Development of matrix metalloproteinase inhibitors in cancer therapy. Hematol Oncol Clin North Am 16(5):1189–1227PubMedCrossRef Purcell WT, Rudek MA, Hidalgo M (2002) Development of matrix metalloproteinase inhibitors in cancer therapy. Hematol Oncol Clin North Am 16(5):1189–1227PubMedCrossRef
32.
33.
go back to reference Rossello A, Nuti E, Catalani MP, Carelli P, Orlandini E, Rapposelli S et al (2005) A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs. Bioorg Med Chem Lett 15(9):2311–2314PubMedCrossRef Rossello A, Nuti E, Catalani MP, Carelli P, Orlandini E, Rapposelli S et al (2005) A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs. Bioorg Med Chem Lett 15(9):2311–2314PubMedCrossRef
34.
go back to reference Devel L, Rogakos V, David A, Makaritis A, Beau F, Cuniasse P et al (2006) Development of selective inhibitors and substrate of matrix metalloproteinase-12. J Biol Chem 281(16):11152–11160PubMedCrossRef Devel L, Rogakos V, David A, Makaritis A, Beau F, Cuniasse P et al (2006) Development of selective inhibitors and substrate of matrix metalloproteinase-12. J Biol Chem 281(16):11152–11160PubMedCrossRef
Metadata
Title
Implication of MMP-9 and urokinase plasminogen activator (uPA) in the activation of pro-matrix metalloproteinase (MMP)-13
Authors
Kyoung Soo Kim
Yeon-Ah Lee
Hyun Mi Choi
Myung Chul Yoo
Hyung-In Yang
Publication date
01-10-2012
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 10/2012
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-011-2095-4

Other articles of this Issue 10/2012

Rheumatology International 10/2012 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.